EXEVIOR TECHNOLOGIES LTD
EXEVIOR TECHNOLOGIES LTD
Industry:
Hardware
Founded:
2007-05-01
Address:
Paphos, Paphos, Cyprus
Country:
Cyprus
Website Url:
http://www.exevior.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
SPF Domain Not Resolving IPv6 Google Apps For Business ReCAPTCHA Cloudflare Hosting Cloudflare DNS ReCAPTCHA V2
Similar Organizations
SolarFlexes
Solar Hardware Manufacturer
Uploud Audio
Loudspeaker manufacturer
Founder
Official Site Inspections
http://www.exevior.com
- Host name: 104.21.94.135
- IP address: 104.21.94.135
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Exevior Technologies Ltd"
Our team - ExeVir
Professor Xavier Saelens, scientific founder of Exevir is a Group Leader at the VIB-UGent Center for Medical Biotechnology at VIB and a full Professor Molecular Virology at Ghent University. …See details»
ExeVir Bio - Crunchbase Company Profile & Funding
ExeVir Bio is a Belgium-based company that develops single-domain antibody-based therapies that help patients ward off viral infections. The company is harnessing a llama-derived antibody technology platform to generate robust …See details»
Board of directors - ExeVir
Chair of the Board & Interim CEO. Professor Michel Kazatchkine, joining as an independent director, brings over 35 years of experience in global health and has played key roles in various organizations, serving as Director of the National …See details»
ExeVir Company Profile 2024: Valuation, Funding
What is the size of ExeVir? ExeVir has 19 total employees. What industry is ExeVir in? ExeVir’s primary industry is Drug Discovery. Is ExeVir a private or …See details»
ExeVir Bio - Devex
Learn more about ExeVir Bio's jobs, projects, latest news, contact information and geographical presence. RAPID VIRAL CONTROL IN A WORLD THAT NEEDS IT ExeVir is a clinical stage …See details»
Belgium: ExeVir lands European venture debt financing …
Jan 9, 2023 The European Investment Bank (EIB) and ExeVir BIO BV (ExeVir) have signed a €25 million venture debt financing agreement to advance the development of ExeVir’s novel COVID-19 therapeutic. The financing is part of …See details»
ExeVir Bio - Craft
ExeVir Bio is a company that harnesses a llama-derived antibody technology platform to generate antiviral therapies providing broad protection against coronaviruses. It’s lead candidate, …See details»
ExeVir Announces Michael Garrett as New Chief Executive Officer
GHENT, Belgium, Nov. 18, 2024 (GLOBE NEWSWIRE) -- ExeVir Bio, a biotech company developing heavy chain-only antibodies targeting highly conserved epitopes for broad …See details»
ExeVir Announces Close of US$50 million / EUR42 million ... - PR …
GHENT, Belgium, March 16, 2021 /PRNewswire/ -- ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that it …See details»
ExeVir Bio and VIB Announce Data on a New Therapy for …
Mar 14, 2023 ExeVir’s COVID-19 pipeline includes XVR012, which is a combination product of the S2-targeting single-domain antibody-based XVR013 reported in the pre-print paper, and …See details»
ExeVir and Mithra announce manufacturing collaboration for …
Jul 15, 2021 Torsten Mummenbrauer, CEO of ExeVir Bio, said: "We are very pleased to collaborate with Mithra which has built a cutting-edge new fill and finish manufacturing facility. …See details»
ExeVir Bio Announces Positive Virus Neutralization Data for
Jan 15, 2024 ExeVir is a spin out of VIB, the leading Belgium-based life sciences research institute. It is backed by strong investors including Fund+, which led the series A of EUR 42 …See details»
ExeVir Announces First Patient Enrolled in Phase 1b/2 Clinical …
GHENT, Belgium, Sept. 1, 2021 /PRNewswire/ -- ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that …See details»
ExeVir Bio Announces Exceptional Virus Neutralization
Jun 4, 2024 ExeVir has received support from VLAIO, the SPW-Recherche and the European Union, leading to a total of EUR 18 million in non-dilutive funding. In 2023, ExeVir secured an …See details»
XVR013m - Drug Targets, Indications, Patents - Synapse
XVR013m, a broadly neutralizing VHH-FC antibody consistently shows exceptional neutralization potency across both SARS-CoV-2 pre-Omicron and Omicron variantsGHENT, Belgium, Oct. …See details»
Dengue - ExeVir
* World Health Organization, 2019, Ten threats to global health in 2019 ** Ebi KL, 2016, Dengue in a changing climate ... ExeVir Bio BV Website by Turnstone Communications. Manage …See details»
Empowering the Immunocompromised and Elderly: ExeVir Bio …
Oct 17, 2024 ExeVir's XVR013m, COVID-19 program focuses on addressing the high unmet medical need to protect and treat immunocompromised and elderly individuals that account for …See details»
ExeVir Bio Forges Ahead with Unique Next Generation COVID-19 …
Oct 20, 2022 ExeVir is building an exciting progressive pipeline with its initial focus on SARS COV-1 & 2 in the immunocompromised. It has progressed XVR011 from research to the clinic …See details»
ExeVir announces first subjects dosed in Phase I clinical study of ...
Aug 18, 2021 ExeVir Bio Fiona du Monceau, COO Email: [email protected] Optimum Strategic Communications Mary Clark, Stella Lempidaki, Zoe Bolt Tel: +44 (0) 20 950 9144 Email: …See details»